Novartis and Genmab submit variation to EMA Marketing Authorization for Arzerra

7 July 2015
genmab-big

Swiss drug major Novartis (NOVN: VX) has submitted a variation to the Marketing Authorization with the European Medicines Agency for the use of Arzerra (ofatumumab) as a maintenance therapy for patients with relapsed chronic lymphocytic leukemia.

This submission has been made in conjunction with its Arzerra partner, Danish drugmaker Genmab (OMX: GEN), and the application is based on interim results from a Phase III study, PROLONG. This evaluated ofatumumab maintenance therapy versus no further treatment in patients with a complete or partial response after second or third line treatment for chronic lymphocytic leukemia.

Jan van de Winkel, chief executive of Genmab, said: “The PROLONG study showed the potential of using ofatumumab as an ongoing maintenance therapy for patients with relapsed CLL. We are pleased that Novartis has taken the next step with ofatumumab in this setting by submitting a regulatory application to the EMA.”

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical